Corcept Therapeutics Announces Commencement Of Next Phase 3 Study With CORLUX(R) For The Treatment Of Psychotic Depression

This is an interesting development for treating psychotic depression, particularly, for dealing with the serious side of this illness, which is causing premature death and more illnesses associated with it. The information indicates that FDA is looking forward to make a quick approval due to the urgency of treating psychotic depression, and in the absence of any suitable drug, CORLUX is likely to...

Corcept Therapeutics is at it again with yet another clinical trial for its lead candidate mifeprisotone (Corlux), a GR-II (glucocorticoid) receptor antagonist, hoping to show efficacy on the psychotic features of psychotic major depression (PMD).   Corlux clearly offers a potentially novel paradigm unlike anything presently on the market for treating psychiatric disorders – it targets the...